Research News and Research

RSS

Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited today announced that brentuximab vedotin (SGN-35) will be featured in two oral presentations at the 52nd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 4-7, 2010 in Orlando, FL.

9 Nov 2010

European study indicates cardiovascular deaths can be avoided through better preventative care

Cardiovascular disease (CVD) is the leading cause of death in Europe, killing an estimated 4.3 million people each year. Results from a large pan-European study announced today indicate that many of these deaths could be avoided if at-risk patients received better preventative care.

9 Nov 2010

Smoking increases risk of breast cancer progression in multiethnic women with breast cancer

Being a current smoker or having a history of smoking significantly increased the risk of breast cancer progression and overall death among a group of multiethnic women with breast cancer, according to the results of a large prospective cohort study.

9 Nov 2010

New approach to treat castration resistant prostate cancer

A monoclonal antibody targeting a well known cell surface protein inhibited prostate cancer growth and metastasis in an aggressive form of the disease that did not respond to hormone therapy, according to a study by researchers with the UCLA Department of Urology and UCLA's Jonsson Comprehensive Cancer Center.

9 Nov 2010

Genetic region linked to survival in patients with advanced bowel cancer

Scientists have discovered a genetic region linked to survival in patients with advanced bowel cancer, according to a study being presented at the National Cancer Research Institute (NCRI) Cancer Conference today (Tuesday).

9 Nov 2010

New TB-drugome may help identify protein targets for tuberculosis

Researchers at the University of California, San Diego School of Medicine and the University of Leeds have linked hundreds of federally approved drugs to more than 1,000 proteins in Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), opening new avenues to repurpose these drugs to treat TB.

9 Nov 2010

Sugar-sweetened drinks can increase gout risk in women

Women who consume fructose-rich beverages, such as sugar-sweetened soft drinks and orange juice, are at an increased risk for gout, according to research presented at the Nov 2010, American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

Chemotherapy for breast cancer does more harm than good

A fundamental principle of medicine is: "first, do no harm." However, for doctors who treat breast cancer, this is easier said than done. Every year, almost 22,000 Canadian women are diagnosed with breast cancer - their treatment usually involves surgery to remove a tumour and then chemotherapy to reduce the risk of cancer returning.

9 Nov 2010

EVP-6124 receptor acts as co-agonist with ACh to enhance cognition

EnVivo Pharmaceuticals today announced it has discovered that EVP-6124, its alpha-7 nicotinic acetylcholine receptor agonist, possesses a novel mechanism not previously seen in the scientific community: it acts as a co-agonist with Acetylcholine (ACh) to enhance cognition.

9 Nov 2010

Study discovers role of Vav1 oncogene in several cancers

Researchers at the Hebrew University of Jerusalem have discovered that Vav1 - an oncogene (cancer-causing gene) found in recent years to be one of the factors in tumorous tissue growth -- plays a wider role in several types of cancer than had previously been thought. The discovery has implications for further concentration on targeting this gene in cancer research.

9 Nov 2010

Scientists develop nanobioconjugate drug to target brain tumor

Nine years ago, scientists at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute detected a subtle shift occurring in the molecular makeup of the most aggressive type of brain tumors, glioblastoma multiforme. With further study, they found that a specific protein called laminin-411 plays a major role in a tumor's ability to build new blood vessels to support its growth and spread. But technology did not exist then to block this protein.

9 Nov 2010

Genta commences tesetaxel Phase 2b clinical trial as 1st-line chemotherapy for metastatic breast cancer

Genta Incorporated today announced that the Company has initiated a new Phase 2b clinical trial of tesetaxel as 1st-line chemotherapy for women with metastatic breast cancer. Tesetaxel is the leading oral taxane currently in clinical development. The new trial will be conducted at Memorial Sloan-Kettering Cancer Center, New York, NY and at the Accelerated Community Oncology Research Network (ACORN) based in Memphis, TN.

9 Nov 2010

Study confirms defect in sweat gland function as disease biomarker for XLHED

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced key findings of a study exploring novel approaches to the assessment of sweat function in males with XLHED. Affected individuals lack a normal sweat response, placing them at life-long risk for clinically-significant hyperthermia.

9 Nov 2010

Merrimack receives $2.44 million under QTDP program to support cancer research

Merrimack Pharmaceuticals was awarded $2.44 million to support research on 10 of its cancer programs through the Qualifying Therapeutic Discovery Project, a grant program created as part of the Patient Protection and Affordable Care Act of 2010 to advance research in areas of unmet medical need.

9 Nov 2010

Food security conference in The Hague concludes with suggestions for U.N. climate negotiations to incorporate agriculture

Participants in a five-day food security meeting at The Hague "urged U.N. climate negotiators Friday to consider agriculture when drawing up strategies to fight climate change," the Canadian Press reports.

9 Nov 2010

Letter asks G20 leaders to support financial transactions tax to help developing countries

G20 leaders meeting in Seoul this week are being asked to commit to plans for a 'Robin Hood Tax' on financial transactions, politics.co.uk reports.

9 Nov 2010

Interleukin Genetics receives two grants under QTDP program to advance obesity, osteoarthritis genetic research

Interleukin Genetics, Inc. today announced that on November 1, 2010 notification was received that it has been awarded two grants totaling $473,393 by the United States Government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the Company's genetic research projects related to obesity and osteoarthritis.

9 Nov 2010

EpiCept third quarter net loss decreases to $3.2 million

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2010, and provided an update with respect to the Company's key business initiatives.

9 Nov 2010

Insurer news: Anthem Blue Cross and Blue Shield to play 'significant' role in VA. implementation; Cigna report lauds consumer-directed plans

Marking its 75th year in business in Virginia, Anthem Blue Cross and Blue Shield is facing perhaps the biggest challenge in its history with the implementation of the national health care overhaul plan and the company's role in how the reform will be implemented in Virginia will be significant.

9 Nov 2010

Firms pursue new digital technologies to meet stimulus- and health law-fueled provider demand

The Washington Post: "A growing number of companies are joining five-year-old AFrame Digital in offering products that link heath care with mobile and other remote technologies in an effort to increase the quality and reduce the cost of medical treatment. Health-care legislation made heaps of money available to digitize medical records and bolster the industry's information technology, including programs to foster innovation" (Overly, 11/8).

9 Nov 2010

Research News and Research

Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

European study indicates cardiovascular deaths can be avoided through better preventative care

Smoking increases risk of breast cancer progression in multiethnic women with breast cancer

New approach to treat castration resistant prostate cancer

Genetic region linked to survival in patients with advanced bowel cancer

New TB-drugome may help identify protein targets for tuberculosis

Sugar-sweetened drinks can increase gout risk in women

Chemotherapy for breast cancer does more harm than good

EVP-6124 receptor acts as co-agonist with ACh to enhance cognition

Study discovers role of Vav1 oncogene in several cancers

Scientists develop nanobioconjugate drug to target brain tumor

Genta commences tesetaxel Phase 2b clinical trial as 1st-line chemotherapy for metastatic breast cancer

Study confirms defect in sweat gland function as disease biomarker for XLHED

Merrimack receives $2.44 million under QTDP program to support cancer research

Food security conference in The Hague concludes with suggestions for U.N. climate negotiations to incorporate agriculture

Letter asks G20 leaders to support financial transactions tax to help developing countries

Interleukin Genetics receives two grants under QTDP program to advance obesity, osteoarthritis genetic research

EpiCept third quarter net loss decreases to $3.2 million

Insurer news: Anthem Blue Cross and Blue Shield to play 'significant' role in VA. implementation; Cigna report lauds consumer-directed plans

Firms pursue new digital technologies to meet stimulus- and health law-fueled provider demand

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News